



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

February 28, 2020

Via E-mail  
Mr. Franco Valle  
Senior Vice President, Finance  
Eidos Therapeutics, Inc.  
101 Montgomery Street, Suite 2000  
San Francisco, CA 94104

**Re: Eidos Therapeutics, Inc.**  
**Form 10-Q for the quarterly period ended September 30, 2019**  
**Exhibit No. 10.1 License Agreement**  
**Filed October 31, 2019**  
**File No. 001-38533**

**Form 8-K**  
**Exhibit No. 10.1 Loan and Security Agreement**  
**Filed November 18, 2019**  
**File No. 001-38533**

Dear Mr. Valle:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance